Prosecution Insights
Last updated: November 04, 2026
Application No. 19/113,076

USE OF RESIN ACIDS AS DEFENSE GENE INDUCERS FOR BIOTIC STRESS IN PLANTS

Non-Final OA §101§102§103§112
Filed
Mar 19, 2025
Priority
Sep 27, 2022 — FR FR2209793 +2 more
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Action Pin
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
1y 4m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
908 granted / 1356 resolved
+7.0% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
53 currently pending
Career history
1417
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
48.2%
+8.2% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
15.8%
-24.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1356 resolved cases

Office Action

§101 §102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 101/112 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-6 and 11 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claims are directed to “A method of using”, but there does not appear to be an active step, other than the use of the term “using”. As such, it is unclear whether this is a method claim with an active step or a composition claim with an intended use. For purposes of examination, these claims will be read as method claims with any use meeting the limitation. Additionally, the claims are directed to a method of using resin acids, wherein the resin acids are derived from conifers, such as pine stump (see instant claim 6). As such, the resin acids appear to be naturally occurring, and as the conifers “use” the resin acids as part of their natural growth, the ability to provide dense gene induces for biotic stress in the plant would be an inherent function and the claims are then directed to a naturally occurring phenomenon. This category of discoveries is not patentable. See MPEP § 2106.04(b) — Laws of Nature, Natural Phenomena & Products of Nature Claims 1-6 and 11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. As noted above, it is unclear what is mean by “using”, whether this is an active step or an intended use, therefore the claim is indefinite. Note, these claims differ from instant claim 14, where claim 14 requires the active step of applying the composition. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-9, 16, 19, and 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Anderson (Ind. Eng. Chem. (1947) 39 (12): 1664–1667). Anderson discloses resin acids extracted from pine stumps (pg 1665, last ¶). With regards to claims 1 and 11, the claims only require the resin acid and using it as defense gene inducers for biotic stress in a plant. As “use” is not defined, the extraction itself and testing of the extract meet the required active step. While claim 11 requires a solvent, the extract is in a solvent With regards to claims 2, 3, 5, and 6 the claims are directed to a method of use, therefore the method of making limitations are interpreted as product by process limitations and are met where the end product is disclosed. See MPEP 2113(I). With regards to claim 4, the claims are directed to the “use” of a composition, therefore the label given the composition does not render the claims distinct. With regards to claim 7, the rosin was combined and analyzed with toluene to produce extracts (pg 1665, Extraction and Analysis section). With regards to claim 8, the content of resin acids is about 58.7% (pg 1665 last ¶). With regards to claim 9 and 19, terpenes were also found in the extract (pg 1666, Volatiles section). Claims 1-8, 10, 11, 14, and 16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tasci (Acta biologica cracoviensia, Series Botanica., 2020, pp 63-77). Tasci et al teaches the effect of a diterpene resin acid, called dehydroabietic acid as activator of systemic acquired resistance under biotic stress. The role as a signal transmitted in soybean was studied. The pretreatment with DHA caused reduction in salt-induced damage, improvement in biomass, water status, chlorophyll, leaves area, regulation of proline, ROS scavenging ability. Furthermore, DHA had an effect on the expression of WRKY-71 gene that is associated with plant stress responses. DHA changes WRKY-gene expression and induces salt stress signaling pathway. The treatments were always of DHA, DHA+NaCI, NaCI and control. A solution maximum 3.3 mM in ethanol was used for the experiments. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-20 are rejected under 35 U.S.C. 103 as being unpatentable over Tasci (Acta biologica cracoviensia, Series Botanica., 2020, pp 63-77) in view of Sinochem (WO2015/003666). Tasci is discussed above but does not teach the addition of fungicides or the instantly claimed excipients. Sinochem teaches it was known to apply pesticides, such as organic copper or flumorph, for treatment of plant disease. It also teaches the addition of thickeners, preservatives wetting agents, etc, where rosin wetting agent is an option. It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. See MPEP 2144.06. Here, the resin acids and additional pesticides all treat and protect plants. Further, it would have been obvious to add additional known excipients to aid in application and delivery of the composition. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri 9:30am-6:30pm + mid-day flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Mar 19, 2025
Application Filed
Sep 24, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778174
COMPOSITIONS FOR USE IN THE REDUCTION OF NOCICEPTION AND OTHER HEALTH BENEFITS IN INFANTS AND YOUNG CHILDREN
4y 4m to grant Granted Nov 03, 2026
Patent 12782339
SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES
3y 9m to grant Granted Nov 03, 2026
Patent 12779056
AGENT FOR DETECTING INTERACTION BETWEEN TISSUES AND ORGANS
3y 6m to grant Granted Nov 03, 2026
Patent 12778862
STABLE BIOACTIVE GLASS FORMULATIONS
2y 6m to grant Granted Nov 03, 2026
Patent 12778892
RADIOPROTECTIVE COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
1y 12m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
82%
With Interview (+15.3%)
2y 11m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1356 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month